Imaging Study of Immunosuppression for Progressive Lung Fibrosis
Treatments studied
Part of Lungs & breathing clinical trials.
This study uses advanced imaging to see how immunosuppressive medications (like mycophenolate or prednisone) affect lung scarring in patients with certain types of lung fibrosis. You would have imaging scans and breathing tests to track changes over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–80 with chronic hypersensitivity pneumonitis, connective tissue disease–related lung fibrosis, or undifferentiated lung fibrosis (not IPF)
- Starting immunosuppression treatment with mycophenolate mofetil, mycophenolate sodium, and/or prednisone for your lung condition
- Evidence of lung scarring on a recent CT scan (within 1 year)
- Lung function test results showing FVC ≥45% predicted and DLCO ≥25% predicted
- No prior treatment with FDA-approved anti-fibrotic drugs (like nintedanib or pirfenidone)
- No respiratory infection in the past 6 weeks and no smoking in the past 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether advanced MRI scans can better detect and track lung scarring in people with certain types of pulmonary fibrosis. It may help doctors understand how well your treatment is working, without extra radiation from CT scans.
This trial uses a special PET/MRI scan to look for early signs of lung scarring and inflammation using a “collagen-targeting” tracer. It may help doctors better identify early interstitial lung disease (IL D) and track it over time.
This Phase 1 study tests a radioactive imaging agent to help doctors see disease activity in the lungs using PET/MRI scans. It includes healthy volunteers and people with lung cancer, idiopathic pulmonary fibrosis, lung transplant–related lung problems, or certain medication-related lung inflammation.
This study is for people with a specific type of lung scarring (not IPF) to understand how the disease progresses. Researchers will collect detailed health information, imaging, and blood samples to learn more about the condition.
This study is testing a new way to track lung scarring (fibrosis) over time in people with conditions like IPF, other fibrotic lung diseases, or early signs of scarring. It might help doctors understand how the disease changes.
This trial tests whether combining two medications—nerandomilast (a new anti-inflammatory drug) and mycophenolate (an immunosuppressant you may already be taking)—can safely slow lung scarring in people with pulmonary fibrosis other than IPF. The goal is to help doctors decide if this combination is right for you.
Hear when a new Interstitial Lung Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.